Valneva announces major COVID-19 vaccine partnership with UK government
UK government invests in Valneva's manufacturing facility and secures supply of 60 million doses of Valneva's inactivated COVID-19 vaccine VLA2001, with option for another 130 million doses.
MVM Summer 2020 Newsletter
Recent updates regarding MVM team, new investments, and portfolio.
MVM invests in Paragon 28
MVM co-led the Series B financing of Paragon 28, a leading orthopedic foot and ankle company.
Valneva confirms participation in UK government COVID-19 vaccine response program
Valneva has reached agreement in principle with the UK government to provide up to 100 million doses of its SARS-CoV-2 vaccine candidate.
MVM invests in MDxHealth SA
MVM closed a growth investment in MDxHealth SA, a company that markets tests that optimize the care of patients with prostate cancer.
MVM leads investment round in SkyCell
MVM led the growth investment round in SkyCell, a company that has developed patented temperature-control technology to transport vaccines and biotechnology drugs.
Valneva and Pfizer announce collaboration on Lyme Disease vaccine, VLA-15
Valneva and Pfizer announced a collaboration to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.
MVM Partners LLP Closes Fund V
MVM Partners announces the closing of a $325 million healthcare fund, MVM V.
HLS Therapeutics announces Health Canada approval for Vascepa® to reduce the risk of cardiovascular events
HLS Therapeutics announces that Health Canada has approved the use of Vascepa® to reduce the risk of cardiovascular events in statin-treated patients with elevated triglycerides, who are at high risk of cardiovascular events due to established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor.
Biotheranostics launches Not Another Minute campaign for its Breast Cancer Index® test
Biotheranostics announces the launch of its Not Another minute campaign, revealing how Breast Cancer Index is changing the game for early-stage, hormone receptor-positive breast cancer patients.